Summary not available.
Summary not available.
Summary not available.
Summary not available.
GlobeStar Therapeutics Corporation (GSTC), a clinical stage pharmaceutical company, is developing a patented formulation for treating Multiple Sclerosis (MS). Recently, GSTC participated in the 29th annual Race to Erase MS Gala, enhancing its visibility among MS experts and potential collaborators. The company is conducting promising studies, including a pharmacokinetics study and initial clinical trials initiated in Italy, where all participants reported improvements in mobility and control after treatment. The global market for MS drugs is projected to reach $33.46 billion by 2026.
Summary not available.
GlobeStar Therapeutics Corporation (OTCQB:GSTC) has appointed New York Bay Capital, LLC as its financial advisor and private placement agent. This strategic move aims to attract accredited investors under SEC guidelines, facilitating clinical trials for its patented solution targeting neuromuscular diseases, including Muscular Dystrophy. The CEO, James C. Katzaroff, emphasized the significance of this partnership in progressing toward impactful treatments for chronic conditions like Multiple Sclerosis.
GlobeStar Therapeutics Corporation (OTCQB:GSTC) announced its intention to explore the potential link between Muscular Dystrophy and Parkinson's disease. The company's CEO, James C. Katzaroff, emphasized the need for thorough research to determine if their proprietary treatment for Muscular Dystrophy could also benefit Parkinson's patients. GlobeStar's mission focuses on addressing neurodegenerative diseases, aiming to enhance the quality of life for those affected. The research initiative reflects the company's commitment to innovative healthcare solutions.
GlobeStar Therapeutics Corporation (OTCQB:GSTC) has officially upgraded from the OTC Pink tier to the OTCQB tier, maintaining the same ticker symbol. This transition, announced on October 11, 2021, reflects the company’s commitment to growth and development in the medical research sector, particularly focusing on neurodegenerative diseases. President and CEO James C. Katzaroff emphasized the importance of this move as a sign of confidence in the company's potential to deliver innovative healthcare solutions. GlobeStar aims to improve the lives of patients with chronic diseases.
GlobeStar Therapeutics Corporation (OTC PINK:GSTC) announced significant progress in negotiations with a major medical center in the Northeast, moving closer to initiating clinical trials for a new drug targeting Multiple Sclerosis and other neurodegenerative diseases. This advancement underscores their commitment to developing effective healthcare solutions for over 4 million annual diagnoses in the U.S. The team is dedicated to presenting their patented drug to the FDA for approval, reflecting a proactive approach to tackling life-altering conditions.